✦ LIBER ✦

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,

✍ Scribed by Miriam M. Treggiari; Margaret Rosenfeld; Nicole Mayer-Hamblett; George Retsch-Bogart; Ronald L. Gibson; Judy Williams; Julia Emerson; Richard A. Kronmal; Bonnie W. Ramsey

Book ID: 116350792
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 555 KB
Volume: 30
Category: Article
ISSN: 1551-7144
DOI: 10.1016/j.cct.2009.01.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidemiologic study of cystic fibrosis:

Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

✍ Wayne J. Morgan; Steven M. Butler; Charles A. Johnson; Andrew A. Colin; Stacey C 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 2 views

## for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis Summary. Cystic fibrosis (CF) is a complex illness characterized by chronic lung infection leading to deterioration in function and respiratory failure in over 85% of patients. An understanding of the risk fact

The MINERVA study design and rationale:

The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias

✍ Reinhard C. Funck; Giuseppe Boriani; Antonis S. Manolis; Helmut Püererfellner; L 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 241 KB

The Early Glycoprotein IIb/IIIa Inhibiti

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Study design and rationale for the clini

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

✍ Harvey White; Claes Held; Ralph Stewart; David Watson; Robert Harrington; Andrze 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 341 KB

A study to assess the effects of a broad

A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: The ACCLAIM trial rationale and design

✍ Guillermo Torre-Amione; Robert C. Bourge; Wilson S. Colucci; Barry Greenberg; Cr 📂 Article 📅 2007 🏛 Pulsus Group Inc 🌐 English ⚖ 294 KB

Rationale, design, and baseline characte

Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure

✍ Fox, Kim; Ford, Ian; Steg, Philippe Gabriel; Tardif, Jean-Claude; Tendera, Micha 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 459 KB